Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Cancer Research and Clinic ; (6): 526-531, 2023.
Article in Chinese | WPRIM | ID: wpr-996269

ABSTRACT

Objective:To investigate the factors influencing the prognosis of patients with estrogen receptor (ER)-positive de novo stage Ⅳ breast cancer.Methods:The clinical data of 339 patients with ER-positive de novo stage Ⅳ breast cancer treated in Tianjin Medical University Cancer Hospital and Cangzhou Hospital of Integrated TCM-WM from February 2010 to December 2017 were retrospectively analyzed. Related factors such as age, time of chief complaint, the clinical T/N stage, site of metastasis, expressions of molecular markers and treatment mode were included. Univariate log-rank test and multivariate Cox regression model were used to analyze the effects of prognostic factors on patients' overall survival (OS).Results:Univariate analysis showed that there were statistically significant differences in the OS of patients stratified by clinical N stage at first diagnosis, metastasis sites at first diagnosis, ER expression, progesterone receptor (PR) expression, Ki-67 positive index and p53 expression, endocrine therapy, chemotherapy at first diagnosis, surgery and radiotherapy of the primary lesions (all P < 0.01). Multivariate Cox regression analysis results showed that metastasis sites at first diagnosis, Ki-67 positive index, surgery and radiotherapy of the primary lesions were all independent influencing factors of OS for breast cancer patients (all P < 0.01). Conclusions:Patients with ER-positive de novo stage Ⅳ breast cancer have a good prognosis when they have oligometastasis, Ki-67 positive index ≤ 20%, and they receive surgery and radiotherapy of the primary lesions.

2.
Journal of Experimental Hematology ; (6): 1251-1255, 2020.
Article in Chinese | WPRIM | ID: wpr-827131

ABSTRACT

OBJECTIVE@#To investigate the influence of influence of combination with 1q21 amplification or-no in patients with newly diagnosed MM on the clinical effecacy of bortezomib-based induction chemotherapy and long-term prognosis of patients.@*METHODS@#148 patients with newly diagnosed MM treated from January 2010 to May 2018 were selected and divided into 2 groups: group A (70 patients) without 1q21 amplification and group B (78 patients) with 1q21 amplification; and the survival benefit and influence on clinical efficacy of bortezomib were compared between 2 groups, and the factors influencing clinical prognosis in the patients with newly diagnosed MM were analyzed.@*RESULTS@#The median PFS and OS of patients in B group were significantly shorter than those in group A (P<0.05). There was no significant difference in the median OS and PFS between patients with 1q21 amplification copies number =3 and >3 (P>0.05). Multivariate Cox model analysis indicated that the adverse factors for OS were ISS staging, Hb levels, β2 microglobulin levels and 1q21 amplification respectively, and the adverse factors for PFS were Hb levels and 1q21 amplification respectively in patients with newly diagnosed MM (P<0.05). The very good partial remission rate of newly diagnosed MM patients with 1q21 amplification and bortezomib-based induction chemotherapy were significantly higher than that in the patients without bortezomib-based induction chemotherapy (P<0.05). The median PFS time of newly diagnosed MM patients with 1q21 amplification and auto-HSCT after bortezomib-based induction chemotherapy was significantly longer than that of patients without auto-HSCT (P<0.05).@*CONCLUSION@#1q21 amplification should be the independent risk factor for poor prognosis of patients with newly treated MM. The application of bortezomib-containing induction chemotherapy in patients with 1q21 amplification can efficiently improve the remission rate, while auto-HSCT consolidation therapy may prolong patients' PFS.


Subject(s)
Humans , Antineoplastic Combined Chemotherapy Protocols , Bortezomib , Therapeutic Uses , Disease-Free Survival , Induction Chemotherapy , Multiple Myeloma , Drug Therapy , Prognosis , Retrospective Studies , Treatment Outcome
3.
National Journal of Andrology ; (12): 99-102, 2019.
Article in Chinese | WPRIM | ID: wpr-816853

ABSTRACT

Female sexual dysfunction (FSD) is a disease associated with various factors such as psychological conditions, age, physical illness, and drugs. Magnetic resonance imaging (MRI) has the advantages for the studies FSD due to its non-invasiveness and high soft-tissue contrast. Brain MRI revealed significant differences in brain function activation sites and signaling between women with FSD and those with normal sexual function. Pelvic MRI found a close relation of the location and size of the clitoris with the sexual function of women, which may help to determine the lesion area of the FSD patient. A comparative analysis of the central nervous system and peripheral reproductive organs in women with normal sexual function and FSD patients by MRI is of great value for exploring the etiology of FSD and its treatment options.

4.
Chinese Journal of Clinical Oncology ; (24): 291-296, 2018.
Article in Chinese | WPRIM | ID: wpr-706796

ABSTRACT

Objective:To investigate the association between indoleamine 2,3-dioxygenase(IDO)expression in tumor tissue,its periph-eral blood activity, and the efficacy of neoadjuvant chemotherapyin patients with breast cancer. Methods: Immunohistochemistry (IHC)and high-performance liquid chromatography(HPLC)were used to measure IDO protein expression in tumor tissue,and kynuren-ine(Kyn),tryptophan(Trp),and IDO activity(Kyn/Trp)in peripheral blood before neoadjuvant chemotherapy in 53 patients with breast cancer from Tianjin Medical University Cancer Institute and Hospital between September 2015 and December 2016.The correlations between the expression and activity of IDO and the efficacy of chemotherapy were analyzed.Results:In tumor tissue,IDO expression-before neoadjuvant chemotherapy was related to clinical tumor stages(P=0.006),node stages(P=0.020),clinical stages(P=0.045),and estrogen receptor(ER)status(P=0.014).High IDO activity before neoadjuvant chemotherapy in peripheral blood was associated with high IDO expression in tumor tissue(P=0.004),and was also correlated with clinical tumor stages(P=0.019)and node stages(P=0.047). Univariate analysis showed that the clinical efficacy of neoadjuvant chemotherapy was associated with pre-chemotherapeutic clinical tumor stages(P=0.049),ER status(P=0.025),and molecular subtype(P=0.014),while pathologic complete response(pCR)was related to pre-chemotherapeutic clinical tumor stages(P=0.014).Importantly,the clinical efficacy of neoadjuvant chemotherapy and pCR were both related to IDO expression and activity before chemotherapy(all P<0.05).Multivariate analysis showed that pre-chemotherapeu-tic IDO activity in peripheral blood was the only independent factor that affected pCR(P=0.032).Conclusions:Tumor tissue IDO expres-sion and peripheral blood IDO activity before chemotherapy were associated with chemotherapy efficacy,and could provide promising information for the clinical prediction of chemotherapy sensitivity.

5.
Chinese Journal of General Surgery ; (12): 211-214, 2017.
Article in Chinese | WPRIM | ID: wpr-608252

ABSTRACT

Objective To investigate the clinicopathologic characteristics and prognosis of medullary breast carcinoma.Methods We conducted a retrospective analysis on clinical and pathologic data of 166 patients with medullary breast cancer.Results All the patients were female with a median age of 52 years old.The proportion of patients with stage Ⅰ,Ⅱ and Ⅲ disease was 16.9%,68.1%,15.0%,respectively.The Luminal,HER-2 overexpressing and triple-negative subtypes constituted 31.3%,8.4%,and 60.3%,respectively.There was significant difference in regional lymph node status of medullary breast cancer patients with different molecular types (x2 =18.248,P =0.003),but not in tumor size,TNM stage,histological grade,and expression of Ki67 (all P > 0.05).Multivariate survival analysis indicated that TNM stage was an independent predictor in the prognosis of medullary breast cancer (HR =5.664,P =0.001).All the patients were followed up from 15 months to 145 months with a median follow-up time of 108 months.The 5-year survival rate was 91.5% and the 10-year survival rate was 87.2%.Conclusions The prognosis of medullary breast cancer is favorable.Personalized treatment according to the TNM stage and histopathologic characteristics achieve a favorable prognosis.

6.
Journal of Medical Informatics ; (12): 31-33, 2017.
Article in Chinese | WPRIM | ID: wpr-669292

ABSTRACT

From the perspective of information technology,the paper designes and implementes the queuing & calling system in the complex environment of specialized hospitals according to actual circumstances and characteristics of out-patient and examination areas,and introduces the architecture,operating process,comparison of effects before and after the optimization,specific application of the system.After launched and used,the system can improve the order in various areas and enhance the satisfaction of both doctors and patients.

7.
Chinese Journal of General Surgery ; (12): 397-401, 2017.
Article in Chinese | WPRIM | ID: wpr-618657

ABSTRACT

Objective To explore the clinicopathological characteristics and prognosis of invasive micropapillary carcinoma of the breast (IMPC),and the distinction between IMPC and invasive ductal carcinoma of the breast (IDC).Methods From February 2004 to November 2013,195 IMPC patients and 420 IDC patients were analyzed retrospectively.Results There were significant differences in mammilla invasion,lymph vessel invasion,orange peel sign,soft tissue encroachment,neoadjuvant chemotherapy,radical mastcctomy,lymph node metastasis,clinical stages,tumor size,lymph node staging,estrogen receptor (ER),progestin receptor (PR),human epidermal growth factor receptor 2 (HER2),molecular subtyping,ratio of radiation,ratio of endocrine therapy,disease-free survival (DFS),overall survival (OS)between the two groups,all P <0.05.Patients with IMPC had lower 5-year DFS and OS rates (68.2% and 73.8%,respectively) than IDC patients (85.7% and 88.6%,respectively),all P < 0.05.In IMPC patients with positive ER/PR,HER2-negative,smaller tumor volume,less lymph node metastasis,negative nipple invasion,negative lymphatic vessel tumor thrombus,negative orange peel change had higher 5-year DFS and OS rates than those with negative ER/PR,HER2 overexpression,larger tumor volume,more lymph node metastasis,positive nipple invasion,positive lymphatic vessel tumor thrombus,positive orange peel change,all P < 0.05.Besides,the patients with pathologic stage Ⅰ had higher OS than those with stage Ⅲ (P < 0.05).Cox regression analysis found that orange peel change,lymph vessel invasion and HER2 were the independent risk factors for the survival time of patients with IMPC.Conclusions IMPC patients have lower DFS and OS compared with IDC.

8.
Korean Journal of Anesthesiology ; : 433-437, 2005.
Article in Korean | WPRIM | ID: wpr-205112

ABSTRACT

Toxic epidermal necrolysis (TEN) is one of the most dramatic, life-threatening cutaneous drug reaction. TEN is characterized by extensive detachment of the epidermis due to full-thickness necrosis. Because of extensive epidermal loss, these patients are vulnerable to infection, fluid loss, electrolyte imbalance, and heat loss. Anesthesiologist should attempt to prevent further skin damage and reduce complications such as pulmonary edema, renal failure, and sepsis. A 30-year-old male patient was admitted with fever and myalgia. 1 day after admission, scale, erosion, ulceration, eruption on skin and mucosa were developed. Symptoms progressed to TEN after 5 days of admission. 6 days after admission, he developed panperitonitis due to duodenal ulcer perforation, and underwent laparotomy under general anesthesia. We report a case of a patient with TEN who received general anesthesia for laparotomy due to panperitonitis.


Subject(s)
Adult , Humans , Male , Anesthesia, General , Body Temperature Regulation , Duodenal Ulcer , Epidermis , Fever , Laparotomy , Mucous Membrane , Myalgia , Necrosis , Pulmonary Edema , Renal Insufficiency , Sepsis , Skin , Stevens-Johnson Syndrome , Ulcer
9.
Chinese Journal of Rheumatology ; (12)2000.
Article in Chinese | WPRIM | ID: wpr-683145

ABSTRACT

Objective To explore the association between ankylosing spondylitis(AS)with the poly- morphism in -308 site of tumor necrosis factor(TNF)-?promoter region. Methods The literature about AS and polymorphism in -308 site of TNF-?promoter region were searched and the meta analysis as performed. Results Eight studies enrolled 987 AS patients and 922 controls in total. The analysis showed that the fre- quencies of alleles and the genotypes had no statistical difference between AS group and the control group [OR=0.86(0.53, 1.38), P=0.53; OR=0.90(0.52, 1.55), P=0.69]. But the frequencies of alleles of western origin had statistical difference between AS group and the control group [OR=0.75(0.59, 0.96), P=0.02]; The TNF-?gene promoter polymorphism may play a role in the severity of sacroiliitis[OR=0.37(0.15. 0.90), P=0.03]. Conclusion The meta-analysis reveales that the alleles of -308 site of TNF-?promoter region may be associated with AS in western ethnical group and play a role in the severity of saeroiliitis.

SELECTION OF CITATIONS
SEARCH DETAIL